Over the past several years, new methods of inhibiting estrogen action have been incorporated into the treatment of ER+ breast cancer, including the use of pharmaceutical agents that block ovarian suppression and the development of ER degraders such as SERDs with improved bioavailability. This evidence concerns the gene ESR1 and breast cancer.